ADVERTORIAL
More than you think
Something new is about to drop
As the pharmaceutical industry is undergoing a profound transformation, connecting heritage and innovation to shape the future of life sciences is core. Brenntag is positioning itself at the center of this shift with a balanced model that combines stability, scale and innovation across the life sciences value chain.
Traditional pharma remains a strong growth engine. Brenntag continues to expand across regulated synthesis, excipients, APIs and nutritional health, leveraging deep regulatory expertise, global sourcing and formulation know-how to strengthen its role as a trusted partner in established pharmaceutical markets.
To be at the front of innovation, Brenntag Pharma is developing a focused biopharma portfolio that leverages formulation of biopharmaceuticals such as monoclonal antibodies, recombinant proteins, mRNA vaccines and advanced cell and gene therapies. These are reshaping medicine and growing at double-digit rates globally. This evolution brings new demands for GMP-compliant materials, tighter quality standards, flexible pack sizes and integrated value-added services that ensure product integrity and regulatory compliance.
A cornerstone of the biopharma strategy is the implementation of a state-of-the-art GMP Pharma Hub in EMEA with global reach. The site will integrate value-added services such as GMP liquid blending and dilution, GMP powder down-packing, GMP biobuffer preparation, GMP-compliant sampling and storage services and GDP warehousing, helping customers reduce bottlenecks, accelerate pharmaceutical manufacturing and commercialisation.
“ This is about moving beyond distribution to become a true GMP solutions partner,” says Gust Desmedt, global president of
Brenntag Pharma. The hub also enables closer collaboration with suppliers through co-branded offerings and access to smaller, harder-to-reach customers.
By combining the maturity of traditional pharma with the agility and high-value services required by biopharma, Brenntag is building a resilient, future-ready distribution model. It is a balanced approach designed not just to follow the industry’ s transformation, but also to actively shape the future of life sciences. ● brenntag. com
19